In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Pfizer (PFE – Research Report), with a ...

Shares of this drugmaker have returned +3% over the past month versus the Zacks S&P 500 composite's -1.7% change. The Zacks Large Cap Pharmaceuticals industry, to which Pfizer belongs, has lost 6.7% ...

It's important to keep in mind that Buffett's words and actions don't always follow the path of the majority. This top ...

On Friday, Pfizer Inc (PFE) stock saw a decline, ending the day at $26.59 which represents a decrease of $-0.02 or -0.08% from the prior close of $26.61. The stock opened at $26.7 and touched a low of ...

We recently compiled a list of the 10 Best January Dividend Stocks To Buy. In this article, we are going to take a look at ...

Pfizer Inc. (NYSE:PFE – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the sixteen ratings ...

Shares of Pfizer Inc. (NYSE:PFE – Get Free Report) were down 0.2% during trading on Friday . The company traded as low as $26 ...

Pfizer (NYSE: PFE) stock investors are curious about the valuation and prospects for the healthcare company. *Stock prices ...

PFE's strong economic moat is threatened by upcoming patent expirations, but its oncology segment shows promising growth ...

Pfizer Inc (PFE) stock saw a modest uptick, ending the day at $26.53 which represents a slight increase of $0.11 or 0.42% from the prior close of $26.42. The stock opened at $26.4 and touched a low of ...

The markets have been red hot and many stocks may seem too expensive today. Still, there are some good deals out there to be ...